[go: up one dir, main page]

HN2011000661A - Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual - Google Patents

Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual

Info

Publication number
HN2011000661A
HN2011000661A HN2011000661A HN2011000661A HN2011000661A HN 2011000661 A HN2011000661 A HN 2011000661A HN 2011000661 A HN2011000661 A HN 2011000661A HN 2011000661 A HN2011000661 A HN 2011000661A HN 2011000661 A HN2011000661 A HN 2011000661A
Authority
HN
Honduras
Prior art keywords
treatment
pharmaceutical composition
sexual transmission
infections
pharmaceutically acceptable
Prior art date
Application number
HN2011000661A
Other languages
English (en)
Inventor
Arzola Paniagua Angelica
Pablo Senosiain Pelaez Juan
Barranco Hernandez Gustavo
Garcia Salgado Lopez Raul
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41796784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2011000661(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of HN2011000661A publication Critical patent/HN2011000661A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL SOLIDA QUE COMPRENDE FLUCONAZOL, TINIDAZOL Y CLINDAMICINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS DONDE EL CONTENIDO DE EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES ES SIGNIFICATIVAMENTE MENOR QUE EL CONTENIDO QUE LOS PRINCIPIOS ACTIVOS , EL USO DE DICHA COMPOSICION PARA LA ADMINISTRACION ORAL CON ACTIVIDAD TERAPEUTICA PARA EL TRATAMIENTO DE INFECCIONES DE TRANSMISION SEXUAL.
HN2011000661A 2008-09-04 2011-03-03 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual HN2011000661A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008011321A MX2008011321A (es) 2008-09-04 2008-09-04 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.

Publications (1)

Publication Number Publication Date
HN2011000661A true HN2011000661A (es) 2013-09-16

Family

ID=41796784

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011000661A HN2011000661A (es) 2008-09-04 2011-03-03 Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual

Country Status (13)

Country Link
US (1) US20110166087A1 (es)
EP (1) EP2329819B1 (es)
KR (1) KR101653424B1 (es)
BR (1) BRPI0918593B8 (es)
CA (1) CA2735926C (es)
CO (1) CO6321156A2 (es)
EC (1) ECSP11010941A (es)
ES (1) ES2734280T3 (es)
HN (1) HN2011000661A (es)
MX (1) MX2008011321A (es)
PE (1) PE20110448A1 (es)
UY (1) UY32091A (es)
WO (1) WO2010026469A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768883A (zh) * 2021-08-25 2021-12-10 海南海神同洲制药有限公司 一种高稳定性盐酸克林霉素棕榈酸酯颗粒的制备方法
CN113768885A (zh) * 2021-09-16 2021-12-10 海南海神同洲制药有限公司 一种伏立康唑干混悬剂的制备工艺
CN114306209A (zh) * 2022-01-10 2022-04-12 江苏远恒药业有限公司 一种替硝唑栓的组合物及其制备方法与应用
CN116251067B (zh) * 2023-04-23 2024-06-07 淄博市中心医院 一种氟康唑片、制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094431B2 (en) 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
MXPA02007641A (es) * 2002-08-08 2004-04-02 Alparis Sa De Cv Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
US8309103B2 (en) 2004-01-22 2012-11-13 Alparis, S.A. De C.V. Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage
US20070154516A1 (en) * 2006-01-05 2007-07-05 Drugtech Corporation Drug delivery system
US20080003262A1 (en) * 2006-06-30 2008-01-03 Drugtech Corporation Compositions and therapeutic methods of use

Also Published As

Publication number Publication date
ES2734280T3 (es) 2019-12-05
EP2329819A4 (en) 2011-09-14
MX2008011321A (es) 2010-03-04
CO6321156A2 (es) 2011-09-20
BRPI0918593B8 (pt) 2021-05-25
KR20110050678A (ko) 2011-05-16
BRPI0918593B1 (pt) 2020-11-10
WO2010026469A1 (es) 2010-03-11
EP2329819B1 (en) 2019-05-01
KR101653424B1 (ko) 2016-09-01
ECSP11010941A (es) 2011-06-30
CA2735926A1 (en) 2010-03-11
BRPI0918593A2 (pt) 2018-05-22
PE20110448A1 (es) 2011-07-20
CA2735926C (en) 2016-09-06
US20110166087A1 (en) 2011-07-07
UY32091A (es) 2010-02-26
BRPI0918593A8 (pt) 2018-12-11
EP2329819A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
AR067347A1 (es) Combinacion antihelmintica
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PA8809601A1 (es) Combinación anti-retroviral
MX2020008616A (es) Rocio de fentanilo sublingual.
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
ECSP13012423A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NEUROPATICO
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
HN2011000661A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
CO6470875A2 (es) Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares
CL2008002005A1 (es) Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.
CL2021002430A1 (es) Formulación de tableta vaginal
HN2010001775A (es) Composicion farmaceutica oral que comprende la combinacion de una sal de keterolaco y vitaminas del complejo b
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.